Press Releases
To stay up to date with our development, sign up for a subscription.
2021
2021-08-27 08:30
"We are very pleased that the study is published in Lancet Respiratory Medicine. The results of the study, which is the largest in inhaled sedation, point to the efficacy and safety of isoflurane via AnaConDa as well as the benefits of the therapy...
2021-08-19 07:00
Second quarter 2021 January-June 2021 CEO Comments At the end of July, an important milestone was reached with the gratifying news that we received - earlier than expected - DCP approval for the pharmaceutical product Sedaconda (isoflurane), as well as...
2021-08-13 08:30
The approval applies to the drug Sedaconda (isoflurane)* for administration via the medical device AnaConDa (undergoing name change to Sedaconda ACD) for inhaled sedation in intensive care in France. The application has been approved by the French Medicines...
2021-08-11 08:30
According to the financial calendar, Sedana Medical plans to publish the report for the second quarter 2021 on Thursday August 19 at approximately 07.00 CEST. Sedana Medical hereby invites to a presentation of the report on the same day, where the interim...
2021-07-20 18:00
The application was approved through a decentralized European procedure (DCP) by the German Medicines Agency BfArM (acting as reference country) in consultation with 14 other European Medicines Agencies. “This is the first important step towards...
2021-07-07 15:00
Sedana Medical is working to submit an IND during the fall and expects to receive an approval to conduct two randomized, controlled trials involving approximately 250 patients each, to confirm and ensure safety and efficacy. As previously announced, Sedana...
2021-07-02 08:45
"The new EU Medical Device Regulation (MDR) has been designed to ensure high quality and safety for med tech products and is a real challenge for many companies. Therefore, I am proud of Sedana Medical’s efforts to achieve this milestone in...
2021-06-22 09:00
"It is very positive that the Sedaconda study is receiving this attention in Germany, which is our largest market. The strong study results form the basis for our ongoing market application and if all goes well, we expect to be able to launch the...
2021-05-18 16:00
The board of directors have now resolved that the record date for the share split shall be Thursday, May 27, 2021. Consequently, the last day for trading in the share prior to the split is Tuesday, May 25, 2021, and the first day for trading in the divided...
2021-05-12 08:00
Johannes Doll is currently Chief Commercial Officer (EVP and Chief Commercial Officer) at Orexo, where he worked for almost eight years. Doll has about 16 years of experience from the life science industry, including as a consultant for nearly eight years...